Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments TrialsJuan E. Grunwald, Daniel Martín, Alison Martin et al.|Ophthalmology|2013Cited by 585
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments TrialsEbenezer Daniel, Maureen G. Maguire, Daniel Martín et al.|Ophthalmology|2013Cited by 325
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular DegenerationGui‐Shuang Ying, Daniel Martín, John A. Wells et al.|Ophthalmology|2012Cited by 310
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments TrialsGlenn J. Jaffe, Jiayan Huang, Ebenezer Daniel et al.|Ophthalmology|2013Cited by 291
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments TrialsSumit Sharma, Glenn J. Jaffe, Daniel Martín et al.|Ophthalmology|2016Cited by 228